Ductal Carcinoma in Situ of the Breast
December 2022 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Ductal Carcinoma in Situ of the Breast abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Ductal Carcinoma in Situ of the Breast. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Ductal Carcinoma in Situ of the Breast. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Ductal Carcinoma in Situ of the Breast every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.

1:Survival outcomes after breast-conserving surgery plus radiotherapy compared with mastectomy in breast ductal carcinoma in situ with microinvasion.
Authors:Xia LY, Xu WY, Hu QL
Institution:Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Chengdu Medical College, 278 Baoguang Avenue Middle Section, Xindu District, Chengdu, 610500, Sichuan, China. lylc1023@163.com.
Journal:Sci Rep. 2022 Nov 22;12(1):20132. doi: 10.1038/s41598-022-24630-7.

2:The clinical significance of HER2 expression in DCIS.
Authors:Akrida I, Mulita F
Institution:Department of General Surgery, University General Hospital of Patras, Rion, Greece. joannakrida@yahoo.gr.
Journal:Med Oncol. 2022 Nov 9;40(1):16. doi: 10.1007/s12032-022-01876-9.

3:Ductal Carcinoma In Situ (DCIS) Diagnosed by MRI-Guided Biopsy among BRCA1/BRCA2 Mutation Carriers.
Authors:Faermann R, Friedman E, Kaidar-Person O, Weidenfeld J, Brodsky M, Shalmon A, Halshtok Neiman O, Gotlieb M, Yagil Y, Samoocha D, Madorsky Feldman D, Sklair-Levy M
Institution:Meirav Center for Women's Health and High-Risk Clinic, Sheba Medical Center, Ramat Gan, Israel.
Journal:Breast J. 2022 Oct 27;2022:4317693. doi: 10.1155/2022/4317693. eCollection 2022.

4:Treatment of Mammary Paget Disease: A systematic review and meta-analysis of real-world data.
Authors:Lin CW, Chiang MH, Tam KW
Institution:School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.; Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan; Division of General Surgery, Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan. Electronic address: kelvintam@h.tmu.edu.tw.
Journal:Int J Surg. 2022 Nov;107:106964. doi: 10.1016/j.ijsu.2022.106964. Epub 2022 Oct 26.

5:Learning to distinguish progressive and non-progressive ductal carcinoma in situ.
Authors:Casasent AK, Almekinders MM, Mulder C, Bhattacharjee P, Collyar D, Thompson AM, Jonkers J, Lips EH, van Rheenen J, Hwang ES, Nik-Zainal S, Navin NE, Wesseling J
Institution:Department of Genetics, MD Anderson Cancer Center, Houston, TX, USA.; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands. j.wesseling@nki.nl.
Journal:Nat Rev Cancer. 2022 Dec;22(12):663-678. doi: 10.1038/s41568-022-00512-y. Epub 2022 Oct 19.

6:Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center.
Authors:Nicosia L, Lissidini G, Sargenti M, Bozzini AC, Farante G, Vila J, Oriecuia C, Pagan E, Bagnardi V, Lazzeroni M, Pesapane F, Sangalli C, Galimberti V, Cassano E, Veronesi P
Institution:Department of Breast Radiology, European Institute of Oncology (IEO), IRCCS, 20141, Milan, Italy. luca.nicosia@ieo.it.; Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy. paolo.veronesi@ieo.it.
Journal:Breast Cancer Res Treat. 2022 Nov;196(2):371-377. doi: 10.1007/s10549-022-06689-y. Epub 2022 Sep 17.

7:Impact of Surgical Delay on Tumor Upstaging and Outcomes in Estrogen Receptor-Negative Ductal Carcinoma in Situ Patients.
Authors:Deliere AE, Kuchta KM, Pesce CE, Kopkash KA, Yao KA
Institution:From the Department of Surgery, NorthShore University HealthSystem, Evanston, IL (Deliere, Pesce, Kopkash, Yao).
Journal:J Am Coll Surg. 2022 Nov 1;235(5):788-798. doi: 10.1097/XCS.0000000000000326. Epub 2022 Oct 17.

8:Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience.
Authors:Levy J, Farag F, Cole J
Institution:Ochsner Clinical School, University of Queensland, New Orleans, LA, USA. v-jullevy@ochsner.org.; Ochsner Clinic Foundation, New Orleans, LA, USA.
Journal:Breast Cancer Res Treat. 2022 Nov;196(1):207-213. doi: 10.1007/s10549-022-06735-9. Epub 2022 Sep 9.

9:Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
Authors:Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen YY, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA
Institution:Department of Surgery, University of California San Francisco, San Francisco.
Journal:JAMA Surg. 2022 Nov 1;157(11):1034-1041. doi: 10.1001/jamasurg.2022.4118.

10:Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ.
Authors:Tesch ME, Rosenberg SM, Collins LC, Wong JS, Dominici L, Ruddy KJ, Tamimi R, Schapira L, Borges VF, Warner E, Come SE, Partridge AH
Institution:Dana-Farber Cancer Institute, Boston, MA, USA. ann_partridge@dfci.harvard.edu.
Journal:Ann Surg Oncol. 2022 Dec;29(13):8048-8057. doi: 10.1245/s10434-022-12361-y. Epub 2022 Aug 12.

11:Countercurrents: DCIS or Cancer? Why All the Confusion?
Authors:Narod SA, Sopik V
Institution:Women's College Research Institute, Women's College Hospital, Toronto, ON M5S 1B2, Canada.
Journal:Curr Oncol. 2022 Jul 13;29(7):4936-4940. doi: 10.3390/curroncol29070392.

12:Microinvasive breast cancer and the role of sentinel lymph node biopsy.
Authors:Hacking SM, Leonard KL, Wu D, Banks M, Graves T, Wang L, Yakirevich E, Wang Y
Institution:Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI, 02903, USA. Yihong_Wang@Brown.edu.
Journal:Sci Rep. 2022 Jul 20;12(1):12391. doi: 10.1038/s41598-022-16521-8.

13:Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis.
Authors:Wu SL, Yu X, Mao X, Jin F
Institution:Department of Surgical Oncology and Breast Surgery, the First Affiliated Hospital of China Medical University, No. 155, North Nanjing Street, Shenyang, 110001, Liaoning Province, China. jinfeng@cmu.edu.cn.
Journal:BMC Cancer. 2022 Jul 18;22(1):782. doi: 10.1186/s12885-022-09883-9.

14:Overuse of Axillary Surgery in Patients with Ductal Carcinoma In Situ: Opportunity for De-escalation.
Authors:Piltin MA, Hoskin TL, Day CN, Habermann EB, Boughey JC
Institution:Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA. Boughey.judy@mayo.edu.
Journal:Ann Surg Oncol. 2022 Nov;29(12):7705-7712. doi: 10.1245/s10434-022-12099-7. Epub 2022 Jul 5.

15:Oncological Safety of Skin-Sparing Mastectomy and Immediate Breast Reconstruction in Extensive Ductal Carcinoma In Situ.
Authors:Tamminen A, Meretoja T, Koskivuo I
Institution:Department of Plastic and General Surgery, Turku University Hospital, University of Turku, Turku, Finland. Electronic address: anselm.tamminen@utu.fi.
Journal:J Surg Res. 2022 Nov;279:25-32. doi: 10.1016/j.jss.2022.05.007. Epub 2022 Jun 16.

16:Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Authors:Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R
Institution:Robert H. Lurie Comprehensive Cancer Center of Northwestern University.; National Comprehensive Cancer Network.
Journal:J Natl Compr Canc Netw. 2022 Jun;20(6):691-722. doi: 10.6004/jnccn.2022.0030.

17:DCIS: Risk Assessment in the Molecular Era.
Authors:Knowlton CA, Jimenez RB, Moran MS
Institution:Department of Therapeutic Radiology, Yale School of Medicine; New Haven, CT. Electronic address: Meena.Moran@yale.edu.
Journal:Semin Radiat Oncol. 2022 Jul;32(3):189-197. doi: 10.1016/j.semradonc.2022.01.005.

18:Surgeons' preferences for using sentinel lymph node biopsy in patients with ductal carcinoma in situ.
Authors:Meurs CJC, Til JAV, Menke-Pluijmers MBE, Vet S, Siesling S, Westenend PJ
Institution:CMAnalyzing, Zevenaar, the Netherlands.; Laboratory of Pathology Dordrecht, Dordrecht, the Netherlands.
Journal:PLoS One. 2022 Jun 6;17(6):e0269551. doi: 10.1371/journal.pone.0269551. eCollection 2022.

19:When to stop? Mammographic surveillance in breast cancer survivors aged 70 years and older.
Authors:Luther AZ, Singh K, Ji C, Agrawal A
Institution:Breast Unit, Queen Alexandra Hospital, Cosham, Portsmouth PO6 3LY, UK. Electronic address: Alison_luther@hotmail.com.
Journal:Clin Radiol. 2022 Sep;77(9):650-654. doi: 10.1016/j.crad.2022.04.004. Epub 2022 Jun 2.

20:Treatment Patterns in Women Age 80 and Over With DCIS: A Report From the National Cancer Database.
Authors:Frebault J, Bergom C, Cortina CS, Shukla ME, Zhang Y, Huang CC, Kong AL
Institution:Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee, WI.; Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee, WI; Medical College of Wisconsin Cancer Center, Milwaukee, WI. Electronic address: akong@mcw.edu.
Journal:Clin Breast Cancer. 2022 Aug;22(6):547-552. doi: 10.1016/j.clbc.2022.04.004. Epub 2022 Apr 22.

21:Alcohol consumption, smoking, and invasive breast cancer risk after ductal carcinoma in situ.
Authors:Jordahl KM, Malone KE, Baglia ML, Flanagan MR, Tang MC, Porter PL, Li CI
Institution:Department of Epidemiology, University of Washington, Seattle, WA, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. cili@fredhutch.org.
Journal:Breast Cancer Res Treat. 2022 Jun;193(2):477-484. doi: 10.1007/s10549-022-06573-9. Epub 2022 Mar 27.

22:Local treatment options for young women with ductal carcinoma in situ: A systematic review and meta-analysis comparing breast conserving surgery with or without adjuvant radiotherapy, and mastectomy.
Authors:Chien JC, Liu WS, Huang WT, Shih LC, Liu WC, Chen YC, Chou KJ, Shiue YL, Lin PC
Institution:Department of Radiation Oncology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan.; Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; Department of Pharmacy, School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: pclin@vghks.gov.tw.
Journal:Breast. 2022 Jun;63:29-36. doi: 10.1016/j.breast.2022.03.006. Epub 2022 Mar 12.

23:Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma.
Authors:Nakayama S, Masuda H, Miura S, Kuwayama T, Hashimoto R, Taruno K, Sawada T, Akashi-Tanaka S, Nakamura S
Institution:Department of Breast Surgical Oncology, Showa University Hospital, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan. osau0310@gmail.com.
Journal:Breast Cancer. 2022 Jul;29(4):610-617. doi: 10.1007/s12282-022-01338-0. Epub 2022 Mar 12.

24:Outcome and risk factors for local recurrence after breast conserving surgery in patients affected by ductal carcinoma in situ.
Authors:Tomasicchio G, Picciariello A, Stucci LS, Panebianco A, Montanaro AE, Cirilli A, Punzo C
Institution:M. Rubino Unit of General Surgery, Division of Surgery, Department of Emergency and Organ Transplant (DETO), Aldo Moro University, University of Bari, Bari, Italy - giovannitomasicchio92@gmail.com.; M. Rubino Unit of General Surgery, Division of Surgery, Department of Emergency and Organ Transplant (DETO), Aldo Moro University, University of Bari, Bari, Italy.
Journal:Minerva Surg. 2022 Dec;77(6):536-541. doi: 10.23736/S2724-5691.22.09284-X. Epub 2022 Mar 1.

25:Mastectomy or Margin Re-excision? A Nomogram for Close/Positive Margins After Lumpectomy for DCIS.
Authors:Martins Maia C, Siderides C, Jaffer S, Weltz C, Cate S, Ahn S, Boolbol S, Ru M, Moshier E, Port E, Schmidt H
Institution:Breast Surgical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. pinamac@nychhc.org.
Journal:Ann Surg Oncol. 2022 Jun;29(6):3740-3748. doi: 10.1245/s10434-021-11293-3. Epub 2022 Jan 22.

26:Impact of consensus guidelines for breast-conserving surgery in patients with ductal carcinoma in situ.
Authors:Tremelling A, Aft RL, Cyr AE, Gillanders WE, Glover-Collins K, Herrmann V, Margenthaler JA
Institution:Section of Surgical Oncology, Department of Surgery, Washington University School of Medicine, St Louis, Missouri, USA.
Journal:Cancer Rep (Hoboken). 2022 May;5(5):e1502. doi: 10.1002/cnr2.1502. Epub 2021 Jul 10.

27:Risk of Breast Cancer in Selected Women With Atypical Ductal Hyperplasia Who do not Undergo Surgical Excision.
Authors:Kilgore LJ, Yi M, Bevers T, Coyne R, Marita L, Lane D, Albarracin C, Bedrosian I
Institution:Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Journal:Ann Surg. 2022 Dec 1;276(6):e932-e936. doi: 10.1097/SLA.0000000000004849. Epub 2021 Mar 4.

28:Patterns of aggressiveness: risk of progression to invasive breast cancer by mammographic features of calcifications in screen-detected ductal carcinoma in situ.
Authors:Lilleborge M, Falk RS, Hovda T, Holmen MM, Ursin G, Hofvind S
Institution:Cancer Registry of Norway, Oslo University Hospital, Oslo, Norway.
Journal:Acta Radiol. 2022 May;63(5):586-595. doi: 10.1177/02841851211006319. Epub 2021 Apr 22.

For a FREE PREVIEW of the Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast...
at a Special 20% Discount

Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast

Updated: January 17, 2023
158 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $37.45
  • Less 20% Discount = - $7.10
  • Discounted Price = $30.35(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $31.20
  • Less 20% Discount = - $6.45
  • Discounted Price = $24.75

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: July 8, 2023

What Our Customers Are Saying...

"The MediFocus Guidebook on DCIS was more than adequate for my research on this condition and I would recommend it to anyone wanting the "whole picture". Thank you for providing this excellent service."
Los Angeles, California

"At a very difficult time, your MediFocus Guidebook on Ductal Carcinoma in Situ helped our family make informed decisions. Thank you for your help!"
Metarie, Louisiana

"I was recently diagnosed with DCIS and was looking everywhere for information to get myself educated. The MediFocus Guidebook was very helpful in clarifying everything for me. The information is so well organized that it makes it easy to read and understand. I feel much better now that I've read this Guidebook and have a clearer understanding of the issues that I face. I highly recommend this Guidebook to anyone seeking to understand DCIS."
Ft. Lauderdale, Florida

Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2023 Medifocus, Inc. All rights reserved.